Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05051631 · ClinicalTrials.gov registry record · NA
BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity
A NA study of Breast Cancer, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 1,071
- Enrollment target
- 1
- Study location
NCT05051631: Completed NA study of Breast Cancer, sponsored by Vanderbilt University Medical Center.
NCT05051631 is a NA study of Breast Cancer that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 1,071 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05051631, a NA study of Breast Cancer, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,071 participants
- Enrollment target
- 1
- Study location
Study Summary
The central goal of this study is to test strategies to implement evidence-based breast cancer risk assessment in healthcare clinics in Tennessee. The BRAVE Strategy (Breast cancer Risk Assessment - achieVing Equity) study aims to assess the feasibility, reach, acceptability, and appropriateness of select customized strategies to increase uptake of breast cancer risk assessment. The investigators will achieve these aims through a conducting a stepped-wedge trial conducted in 10 healthcare clinics in the state of Tennessee. The primary outcome is the proportion of women age 25-49 having risk assessment. Secondary outcomes include the numbers of 1) women identified as high-risk; 2) pursuing risk-adherent screening; and 3) diagnosed with breast cancer.
Primary Outcome
The number of women eligible for risk assessment who received documented breast cancer risk assessment.
Conditions Studied
Interventions
- OTHER Intervention plus 12 months maintenance
- OTHER Intervention plus 10 months maintenance
- OTHER Intervention plus 8 months maintenance
- OTHER Intervention plus 6 months maintenance
- OTHER Intervention plus 4 months maintenance
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,071 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2024-08-30 |
| Phase | NA |
What the finished NCT05051631 record still lists
NCT05051631 is an interventional study that assigns participants to a tested intervention. Its 1,071 participants enrollment target places it among the larger protocols in the corpus, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Intervention plus 12 months maintenance is the first listed.
NCT05051631 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT05051631 about?
NCT05051631 is a clinical study titled "BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity". The central goal of this study is to test strategies to implement evidence-based breast cancer risk assessment in healthcare clinics in Tennessee. The BRAVE Strategy (Breast cancer Risk Assessment - achieVing Equity) study aims to assess the feasibility, reach, acceptability, and appropriateness of ...
What is the current status of trial NCT05051631?
This trial is currently completed. It is a NA study. The enrollment target is 1,071 participants. The study started on 2022-03-09. Estimated completion is 2024-08-30.
What conditions does trial NCT05051631 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT05051631?
The interventions under investigation include: Intervention plus 12 months maintenance (OTHER), Intervention plus 10 months maintenance (OTHER), Intervention plus 8 months maintenance (OTHER), Intervention plus 6 months maintenance (OTHER), Intervention plus 4 months maintenance (OTHER).
Who is sponsoring clinical trial NCT05051631?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05051631 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05051631's enrollment target sits among peer trials
1,071 113th of 1224 higher than 1,112 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06751043 · 1,072 participants · NA
Preoperative Fasting vs. Not Fasting in Critically Ill Patients
- NCT06159673 · 1,074 participants · Phase 2
ACP-204 in Adults With Alzheimer's Disease Psychosis
- NCT06658808 · 1,075 participants · NA
Efficacy-Implementation Study for PC CARES in Rural Alaska
- NCT07084883 · 1,076 participants
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI